Unibest
← Back to patent-cliff list

CAS 1033517-35-9

5-[(2alpha,5beta,7beta,10beta,13alpha)-4-(Acetyloxy)-2-(benzoyloxy)-7,10-bis[(3,5-dinitrobenzoyl)oxy]-1-hydroxy-9-oxo-5,20-epoxytax-11-en-13-yl] 3-tert-butyl (2R,4S,5R)-2-(4-methoxyphenyl)-4-phenyl-1,3-oxazolidine-3,5-dicarboxylate

Codes: (XV)140605-15-b

Application context (from source-drug indications)

Non-small cell lung cancerDocetaxel (Beihai)Prostate cancerDocetaxel (Beihai)Castration-resistant prostate cancerDocetaxel (Beihai)Breast cancerDocetaxel (Beihai)Head and neck cancerDocetaxel (Beihai)Head and neck squamous cell carcinomaDocetaxel (Beihai)

Source drugs (routes using this intermediate)

DrugTierExpiry
Docetaxel (Beihai)Tier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.